Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Natalia D. Marchenko
ErbB2 Inhibition by Lapatinib Promotes Degradation of Mutant P53 Protein in Cancer Cells
Oncotarget
Oncology
Unconventional Activation Mechanisms of MMP-26, a Human Matrix Metalloproteinase With a Unique PHCGXXD Cysteine-Switch Motif
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Related publications
PRIMA-1 Inhibits Growth of Breast Cancer Cells by Re-Activating Mutant P53 Protein
International Journal of Oncology
Cancer Research
Oncology
A Gain of Function P53 Gene Mutant Promotes Growth Suppression in Human Liver Cancer Cells
Sains Malaysiana
Multidisciplinary
Autophagy Induced by Saha Affects Mutant P53 Degradation and Cancer Cell Survival
Bioscience Reports
Biochemistry
Cell Biology
Molecular Biology
Biophysics
Inhibition of MDM2-mediated P53 Ubiquitination and Degradation by Ribosomal Protein L5
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
A Novel Mutant P53 Binding Partner BAG5 Stabilizes Mutant P53 and Promotes Mutant P53 GOFs in Tumorigenesis
Cell Discovery
Biochemistry
Genetics
Cell Biology
Molecular Biology
The Role of Mutant P53 Protein in Breast Cancer.
Mechanism of Lapatinib-Mediated Radiosensitization of Breast Cancer Cells Is Primarily by Inhibition of the Raf>MEK>ERK Mitogen-Activated Protein Kinase Cascade and Radiosensitization of Lapatinib-Resistant Cells Restored by Direct Inhibition of MEK
Radiotherapy and Oncology
Nuclear Medicine
Oncology
Radiology
Hematology
Imaging
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated With Lapatinib Resistance and Neoplastic Transformation
Clinical Cancer Research
Cancer Research
Oncology
Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells
Oncogene
Cancer Research
Genetics
Molecular Biology
